Circadian owns Vegenics
Thursday, 14 August, 2008
Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.
Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.
Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.
Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
